DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key bladder cancer patient populations covering 171 countries and more than 99% of the global population, delivered in an interactive dashboard-style download. Use the extended worldwide coverage data set to:

  • View 10-year forecasts of the first-line drug-treatable population and diagnosed incident cases for all 171 countries, stratified by region and World Bank income status.
  • Aggregate country-level estimates into region-level estimates, according to user preference or as required by regulators for orphan drug designations.
  • Visualize global correlations between disease risk or patient population size and key indicators of market opportunity such as GDP per capita and healthcare spend per capita.
  • Generate and export global heat maps of disease risk or patient population size.

The extended worldwide coverage dashboard is available as an Excel file in the “Downloads” section. It is available only to clients with subscriptions to all 45 countries covered by DRG Epidemiology. For subscription and entitlement queries, please contact questions@teamdrg.com.

Table of contents

  • Extrapolated Worldwide Coverage
    • Extrapolated Worldwide Coverage
      • Introduction
      • Download
      • The Global Extrapolator Model
      • The Global Extrapolation Algorithm

Author(s): Mike Hughes, MSc, PhD; Narendra Parihar

Mike joined Decision Resources as an epidemiologist in 2006. He has many years’ experience in the mathematical modeling of healthcare service delivery, cardiovascular and cancer epidemiology, biostatistics, meta-analysis and systematic reviewing. He has been principal author on many published articles in leading international journals in the areas of risk modeling in intensive care and cardiovascular medicine. He has also been responsible for developing national guidelines on behalf of NICE and the American College of Chest Physicians for the treatment of atrial fibrillation, stroke and hypertension. He is particularly interested in modeling patient flows in cancer and methods for forecasting disease burden in non-communicable epidemiology. Dr. Hughes received his in risk modeling in intensive care in 2003 from City University, London and is currently enrolled in a program in statistical causation and foundations of probability theory at the University of Nottingham.

Narendra is an associate epidemiologist within the epidemiology team at Decision Resources Group. Narendra specializes in developing epidemiological forecasts for multiple indications within the DRG syndicated portfolio. His qualifications include an MPH with specialization in Health Policy, Economics and Finance from the Tata Institute of Social Sciences, Mumbai, and a Bachelor’s degree in Dentistry from the Rajasthan University of Health Sciences.


Related Reports

Bladder Cancer | Unmet Need | Detailed, Expanded Analysis (US/EU5)

The FDA approval of five immune checkpoint inhibitors for advanced or metastatic bladder cancer has significantly altered the treatment landscape...

View Details

Bladder Cancer | Geographic Focus: China | China In-Depth

Bladder cancer is one of the most commonly diagnosed cancers and a substantial cause of cancer-related deaths in China. The bladder cancer market is set to enter a competitive and dynamic period...

View Details

Bladder Cancer | Disease Landscape and Forecast | G7 | 2019

The 2016/17 FDA approvals of five immune checkpoint inhibitors for platinum-treated patients have significantly altered the treatment landscape for advanced bladder cancer, which has historically b...

View Details

Bladder Cancer | Landscape & Forecast | Disease Landscape & Forecast

The 2016/17 FDA approvals of five immune checkpoint inhibitors for platinum-treated patients have significantly altered the treatment landscape for advanced bladder cancer, which has historically...

View Details